Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Capper

Showing results (61-70 of 350) with videos related to

Pageof 35
Sort By:
European Journal of Medical Genetics|November 10, 2022
Rare embryonal and sarcomatous central nervous system tumours: State-of-the art and future directionsJohannes Gojo, Mimi Kjaersgaard, Barbara V Zezschwitz, et al.
Nature Communications|February 20, 2025
Explainable artificial intelligence of DNA methylation-based brain tumor diagnosticsSalvatore Benfatto, Martin Sill, David T W Jones, et al.
International Journal of Cancer|September 14, 2011
2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor sizeDavid Capper, Matthias Simon, Claus-Dieter Langhans, et al.
Neuro-Oncology|May 28, 2010
Defective p53 antiangiogenic signaling in glioblastomaBenjamin Berger, David Capper, Dieter Lemke, et al.
Human Pathology|October 24, 2012
Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCRHans Bösmüller, Anna Fischer, Deborah L Pham, et al.
Histopathology|June 29, 2011
Immunohistochemical analysis of 1844 human epithelial and haematopoietic tumours and sarcomas for IDH1R132H mutationFelix Sahm, David Capper, Jochen Meyer, et al.
Pathology, Research and Practice|December 1, 2019
High density DNA methylation array is a reliable alternative for PCR-based analysis of the MGMT promoter methylation status in glioblastomaAnne K Braczynski, David Capper, David T W Jones, et al.
Acta Neuropathologica|August 2, 2013
ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosisBenedikt Wiestler, David Capper, Tim Holland-Letz, et al.
BMC Cancer|February 12, 2016
Chemotherapy with BCNU in recurrent glioma: Analysis of clinical outcome and side effects in chemotherapy-naïve patientsChristine Jungk, Despina Chatziaslanidou, Rezvan Ahmadi, et al.
Journal of Neuropathology and Experimental Neurology|February 28, 2016
Malignant Transformation of a Dysembryoplastic Neuroepithelial Tumor (DNET) Characterized by Genome-Wide Methylation AnalysisDieter Henrik Heiland, Ori Staszewski, Martin Hirsch, et al.
Pageof 35

Showing results (61-70 of 350) with videos related to

Sort By:
Pageof 35
European Journal of Medical Genetics|November 10, 2022
Rare embryonal and sarcomatous central nervous system tumours: State-of-the art and future directionsJohannes Gojo, Mimi Kjaersgaard, Barbara V Zezschwitz, et al.
Nature Communications|February 20, 2025
Explainable artificial intelligence of DNA methylation-based brain tumor diagnosticsSalvatore Benfatto, Martin Sill, David T W Jones, et al.
International Journal of Cancer|September 14, 2011
2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor sizeDavid Capper, Matthias Simon, Claus-Dieter Langhans, et al.
Neuro-Oncology|May 28, 2010
Defective p53 antiangiogenic signaling in glioblastomaBenjamin Berger, David Capper, Dieter Lemke, et al.
Human Pathology|October 24, 2012
Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCRHans Bösmüller, Anna Fischer, Deborah L Pham, et al.
Histopathology|June 29, 2011
Immunohistochemical analysis of 1844 human epithelial and haematopoietic tumours and sarcomas for IDH1R132H mutationFelix Sahm, David Capper, Jochen Meyer, et al.
Pathology, Research and Practice|December 1, 2019
High density DNA methylation array is a reliable alternative for PCR-based analysis of the MGMT promoter methylation status in glioblastomaAnne K Braczynski, David Capper, David T W Jones, et al.
Acta Neuropathologica|August 2, 2013
ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosisBenedikt Wiestler, David Capper, Tim Holland-Letz, et al.
BMC Cancer|February 12, 2016
Chemotherapy with BCNU in recurrent glioma: Analysis of clinical outcome and side effects in chemotherapy-naïve patientsChristine Jungk, Despina Chatziaslanidou, Rezvan Ahmadi, et al.
Journal of Neuropathology and Experimental Neurology|February 28, 2016
Malignant Transformation of a Dysembryoplastic Neuroepithelial Tumor (DNET) Characterized by Genome-Wide Methylation AnalysisDieter Henrik Heiland, Ori Staszewski, Martin Hirsch, et al.
Pageof 35